Seikagaku Corp (4548 JP): Q1 FY03/25 flash update
The company reported YoY increases in sales (3.7%), operating profit (26.3%), recurring profit (11.6%), and net income (0.7%). Pharmaceuticals...
158 Views
Screening the Silk Road: Q1 2021 All Cap Screening - Free Cashflow (FCF)
With the value/growth investment style ratio at 20-year lows, we present 27 names which hold characteristics worthy of further review.
237 Views
Opdivo Singled Out in Government Rule Change
The suggestion of government orchestration against Ono’s immunotherapy treatment Opdivo (nivolumab) has moved a stage further with a report in the...
5.7k Views
No more insights